These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 14978588)

  • 1. [Glutamatergic neurotransmission as molecular target in anxiety].
    Carobrez Ade P
    Braz J Psychiatry; 2003 Dec; 25 Suppl 2():52-8. PubMed ID: 14978588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of defensive responses and anxiety-like behaviors by group I metabotropic glutamate receptors located in the dorsolateral periaqueductal gray.
    Lima VC; Molchanov ML; Aguiar DC; Campos AC; Guimarães FS
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):178-85. PubMed ID: 17804134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The metabotropic glutamate receptors: potential drug targets for the treatment of anxiety disorders?
    Pitsikas N
    Eur J Pharmacol; 2014 Jan; 723():181-4. PubMed ID: 24361306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intra-periaqueductal gray matter injections of midazolam fail to alter anxiety in plus-maze experienced mice.
    dos Reis LM; Canto-de-Souza A
    Brain Res; 2008 Sep; 1231():93-102. PubMed ID: 18621039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulation of 5-HT1A or 5-HT2A receptors in the ventrolateral periaqueductal gray causes anxiolytic-, but not panicolytic-like effect in rats.
    de Paula Soares V; Zangrossi H
    Behav Brain Res; 2009 Jan; 197(1):178-85. PubMed ID: 18801389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel metabotropic glutamate receptor 4 and glutamate receptor 8 therapeutics for the treatment of anxiety.
    Raber J; Duvoisin RM
    Expert Opin Investig Drugs; 2015 Apr; 24(4):519-28. PubMed ID: 25518990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antagonists at metabotropic glutamate receptor subtype 5: structure activity relationships and therapeutic potential for addiction.
    Carroll FI
    Ann N Y Acad Sci; 2008 Oct; 1141():221-32. PubMed ID: 18991960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glutamate receptor ligands as anxiolytics.
    Chojnacka-Wójcik E; Kłodzinska A; Pilc A
    Curr Opin Investig Drugs; 2001 Aug; 2(8):1112-9. PubMed ID: 11892923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NMDA-coupled periaqueductal gray glycine receptors modulate anxioselective drug effects on plus-maze performance.
    De Souza MM; Schenberg LC; de Pádua Carobrez A
    Behav Brain Res; 1998 Feb; 90(2):157-65. PubMed ID: 9521547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analgesic and anxiolytic effects of [Leu
    Vázquez-León P; Mendoza-Ruiz LG; Juan ER; Chamorro-Cevallos GA; Miranda-Páez A
    Neuropeptides; 2017 Dec; 66():81-89. PubMed ID: 29042065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression.
    Hughes ZA; Neal SJ; Smith DL; Sukoff Rizzo SJ; Pulicicchio CM; Lotarski S; Lu S; Dwyer JM; Brennan J; Olsen M; Bender CN; Kouranova E; Andree TH; Harrison JE; Whiteside GT; Springer D; O'Neil SV; Leonard SK; Schechter LE; Dunlop J; Rosenzweig-Lipson S; Ring RH
    Neuropharmacology; 2013 Mar; 66():202-14. PubMed ID: 22551786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition by opioids acting on mu-receptors of GABAergic and glutamatergic postsynaptic potentials in single rat periaqueductal gray neurones in vitro.
    Chieng B; Christie MJ
    Br J Pharmacol; 1994 Sep; 113(1):303-9. PubMed ID: 7812626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guanosine Anxiolytic-Like Effect Involves Adenosinergic and Glutamatergic Neurotransmitter Systems.
    Almeida RF; Comasseto DD; Ramos DB; Hansel G; Zimmer ER; Loureiro SO; Ganzella M; Souza DO
    Mol Neurobiol; 2017 Jan; 54(1):423-436. PubMed ID: 26742520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noradrenaline microinjected into the dorsal periaqueductal gray matter causes anxiolytic-like effects in rats tested in the elevated T-maze.
    Estrada VB; Matsubara NK; Gomes MV; Corrêa FM; Pelosi GG
    Life Sci; 2016 May; 152():94-8. PubMed ID: 26968783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of glutamate in anxiety and related disorders.
    Cortese BM; Phan KL
    CNS Spectr; 2005 Oct; 10(10):820-30. PubMed ID: 16400245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutamate and anxiety.
    Bergink V; van Megen HJ; Westenberg HG
    Eur Neuropsychopharmacol; 2004 May; 14(3):175-83. PubMed ID: 15056476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ventrolateral periaqueductal gray is involved in the cardiovascular response evoked by l-glutamate microinjection into the lateral hypothalamus of anesthetized rats.
    Deolindo M; Pelosi GG; Tavares RF; Aguiar Corrêa FM
    Neurosci Lett; 2008 Jan; 430(2):124-9. PubMed ID: 18035492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of cannabinoid CB1 receptors in the dorsolateral periaqueductal gray induces anxiolytic effects in rats submitted to the Vogel conflict test.
    Lisboa SF; Resstel LB; Aguiar DC; Guimarães FS
    Eur J Pharmacol; 2008 Sep; 593(1-3):73-8. PubMed ID: 18691568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutamate-based anxiolytic ligands in clinical trials.
    Wierońska JM; Pilc A
    Expert Opin Investig Drugs; 2013 Aug; 22(8):1007-22. PubMed ID: 23718208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The glutamatergic system as a target for neuropathic pain relief.
    Osikowicz M; Mika J; Przewlocka B
    Exp Physiol; 2013 Feb; 98(2):372-84. PubMed ID: 23002244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.